Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The mechanism and medical treatment target for degenerative aortic valve disease, including aortic stenosis, is not well studied. In this study, we investigated the effect of clonal hematopoiesis of indeterminate potential (CHIP) on the development of aortic valve sclerosis (AVS), a calcified aortic valve without significant stenosis. Methods: Participants with AVS (valves ≥2 mm thick, high echogenicity, and a peak transaortic velocity of <2.5 m/sec) and an age- and sex-matched control group were enrolled. Twenty-four CHIP genes with common variants in cardiovascular disease were used to generate a next-generation sequencing panel. The primary endpoint was the CHIP detection rate between the AVS and control groups. Inverse-probability treatment weighting (IPTW) analysis was performed to adjust for differences in baseline characteristics. Results: From April 2020 to April 2022, 187 participants (125 with AVS and 62 controls) were enrolled; the mean age was 72.6±8.5 yrs, and 54.5% were male. An average of 1.3 CHIP variants was observed. CHIP detection, defined by a variant allele frequency (VAF) of ≥0.5%, was similar between the groups. However, the AVS group had larger CHIP clones: 49 (39.2%) participants had a VAF of ≥1% (vs. 13 [21.0%] in the control group; P=0.020), and 25 (20.0%) had a VAF of ≥2% (vs. 4 [6.5%]; P=0.028). AVS is independently associated with a VAF of ≥1% (adjusted odds ratio: 2.44, 95% confidence interval: 1.11–5.36; P=0.027). This trend was concordant and clearer in the IPTW cohort. Conclusions: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.
Abstract
Background: The mechanism and medical treatment target for degenerative aortic valve disease, including aortic stenosis, is not well studied. In this study, we investigated the effect of clonal hematopoiesis of indeterminate potential (CHIP) on the development of aortic valve sclerosis (AVS), a calcified aortic valve without significant stenosis. Methods: Participants with AVS (valves ≥2 mm thick, high echogenicity, and a peak transaortic velocity of <2.5 m/sec) and an age- and sex-matched control group were enrolled. Twenty-four CHIP genes with common variants in cardiovascular disease were used to generate a next-generation sequencing panel. The primary endpoint was the CHIP detection rate between the AVS and control groups. Inverse-probability treatment weighting (IPTW) analysis was performed to adjust for differences in baseline characteristics. Results: From April 2020 to April 2022, 187 participants (125 with AVS and 62 controls) were enrolled; the mean age was 72.6±8.5 yrs, and 54.5% were male. An average of 1.3 CHIP variants was observed. CHIP detection, defined by a variant allele frequency (VAF) of ≥0.5%, was similar between the groups. However, the AVS group had larger CHIP clones: 49 (39.2%) participants had a VAF of ≥1% (vs. 13 [21.0%] in the control group; P=0.020), and 25 (20.0%) had a VAF of ≥2% (vs. 4 [6.5%]; P=0.028). AVS is independently associated with a VAF of ≥1% (adjusted odds ratio: 2.44, 95% confidence interval: 1.11–5.36; P=0.027). This trend was concordant and clearer in the IPTW cohort. Conclusions: Participants with AVS more commonly had larger CHIP clones than age- and sex-matched controls. Further studies are warranted to identify causality between AVS and CHIP.
참고문헌 (40)
- Steensma DP, "Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes", Blood, 126, pp.9~16 (2015)
- Jaiswal S, "Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease", N Engl J Med, 377, pp.111~121 (2017)
- Jaiswal S, "Age-related clonal hematopoiesis associated with adverse outcomes", N Engl J Med, 371, pp.2488~2498 (2014)
- Sano S, "Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β", NLRP3 inflammasome, 2018, pp.71, 875~886
- Sano S, "CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease", Circ Res, 123, pp.335~341 (2018)
- Mas-Peiro S, "Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation", Eur Heart J, 41, pp.933~939 (2020)
- Nkomo VT, "Burden of valvular heart diseases : a population-based study", Lancet, 368, pp.1005~1011 (2006)
- Nightingale AK, "Aortic sclerosis : not an innocent murmur but a marker of increased cardiovascular risk", Heart, 91, pp.1389~1393 (2005)
- Di Minno MND, "Cardiovascular morbidity and mortality in patients with aortic valve sclerosis : a systematic review and meta-analysis", Int J Cardiol, 260, pp.138~144 (2018)
- Coffey S, "The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis", J Am Coll Cardiol, 63, pp.2852~2861 (2014)
- Rojulpote C, "Role of 18F-NaF-PET in assessing aortic valve calcification with age", Am J Nucl Med Mol Imaging, 10, pp.47~56 (2020)
- Voigt JU, "Definitions for a common standard for 2D speckle tracking echocardiography : consensus document of the EACVI", ASE, Eur Heart J Cardiovasc Imaging, pp.2015, 16[DOI]
- Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 28, pp.1~39 (2015)
- Karner K, "Current aspects of clonal hematopoiesis : implications for clinical diagnosis", Ann Lab Med, 39, pp.509~514 (2019)
- Steensma DP, "Clinical consequences of clonal hematopoiesis of indeterminate potential", Blood Adv, 2, pp.3404~3410 (2018)
- Sano S, "Clonal hematopoiesis and its impact on cardiovascular disease", Circ J, 83, pp.2~11 (2018)
- Lee KS, "Analytical and clinical validation of cell-free circulating tumor DNA assay for the estimation of tumor mutational burden", Clin Chem, 68, pp.1519~1528 (2022)
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- Chao EC, "Incidental detection of acquired variants in germline genetic and genomic testing : a points to consider statement of the American College of Medical Genetics and Genomics(ACMG)", Genet Med, 23, pp.1179~1184 (2021)
- Stekhoven DJ, "MissForest—non-parametric missing value imputation for mixed-type data", Bioinformatics, 28, pp.112~118 (2012)
- Robins JM, "Marginal structural models and causal inference in epidemiology", Epidemiology, 11, pp.550~560 (2000)
- Belsky DW, "Quantification of biological aging in young adults", Proc Natl Acad Sci U S A, 112, pp.E4104~E4110 (2015)
- Moon I, "Clinical Mutational, and Transcriptomic Characteristics in Elderly Korean Individuals With Clonal Hematopoiesis Driver Mutations", Ann Lab Med, 43, pp.145~152 (2023)
- Zink F, "Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly", Blood, 130, pp.742~752 (2017)
- Hasselbalch HC, "Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?", Blood, 119, pp.3219~3225 (2012)
- Fuster JJ, "Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice", Science, 355, pp.842~847 (2017)
- Svensson EC, "TET2-driven clonal hematopoiesis and response to canakinumab : an exploratory analysis of the CANTOS randomized clinical trial", JAMA Cardiol, 7, pp.521~528 (2022)
- Abplanalp WT, "Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure", Circ Res, 128, pp.216~228 (2021)
- Abplanalp WT, "Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure", JAMA Cardiol, 5, pp.1170~1175 (2020)
- Kiefer KC, "Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality", ESC Heart Fail, 8, pp.1873~1884 (2021)
- Bouchareb R, "Autotaxin derived from lipoprotein(a)and valve interstitial cells promotes inflammation and mineralization of the aortic valve", Circulation, 132, pp.677~690 (2015)
- Thanassoulis G, "Genetic associations with valvular calcification and aortic stenosis", N Engl J Med, 368, pp.503~512 (2015)
- Owens DS, "Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population", JACC Cardiovasc Imaging, 5, pp.619~625 (2012)
- Chandra HR, "Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation", J Am Coll Cardiol, 43, pp.169~175 (2004)
- Stinebaugh J, "Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease", South Med J, 88, pp.65~71 (1995)
- Straumann E, "Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis", Br Heart J, 67, pp.236~239 (1992)
- Ix JH, "Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis(MESA)", Am J Kidney Dis, 50, pp.412~420 (2007)
- Pawade TA, "Effect of denosumab or alendronic acid on the progression of aortic stenosis : a double-blind randomized controlled trial", Circulation, 143, pp.2418~2427 (2021)
- Loomba RS, "Statin therapy and aortic stenosis : a systematic review of the effects of statin therapy on aortic stenosis", Am J Ther, 17, pp.e110~e114 (2010)
- Kim BK, "Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial", Lancet, 400, pp.380~390 (2022)